Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.
The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.
Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.
Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).